CRL's revenue has held near $1.0B across the last ten quarters, suggesting the post-pandemic biotech funding tailwind has largely unwound and top-line growth remains stagnant, with Q3 2026 revenue at $982.7M down 2.2% year over year.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been flat near $1.0B with Q3 2026 net margin at 33.9% inflated by one-off items against a 20.6% operating margin, suggesting reported profitability remains unstable and warrants further investigation.
The company is projected to achieve a 500-basis-point margin expansion in the second half of 2026, which could significantly improve profitability.
Revenue has shown consistent growth, ranging between US$984.2 million and US$1,032.1 million in the first half of FY 2025.
The company possesses a narrow moat, indicating a competitive edge in its industry that supports sustained profitability.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $3.09+4.0% vs $2.97 | $983M+2.3% vs $960M |
Q3 2026 Aug 5, 2026 | $3.02+10.2% vs $2.74 | $1.0B+2.8% vs $977M |
Q2 2026 May 7, 2026 | $2.06+5.1% vs $1.96 | $996M+1.9% vs $977M |
Q1 2026 Feb 18, 2026 | $2.39+2.6% vs $2.33 | $994M+0.7% vs $987M |
Charles River Laboratories International NYSE: CRL raised its 2026 revenue and earnings outlook after third-quarter organic revenue growth accelerated to 4.7%, supported by demand for safety assessment and manufacturing testing services.
Boston Trust Walden Corp reduced its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 13.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 251,380 shares of the medical research company's stock after selling 37,537 shares during the quarter.
Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript
CRL beats Q3 earnings and revenue estimates as organic growth and margin expansion drive results, prompting the company to raise its 2026 outlook.
Benchmark CRL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Charles River Laboratories International, Inc. (CRL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $337.52 | $16.26B | 408.03 | -0.85% | 1.01% | 1.3% | — | |
| $271.83 | $44.74B | 32.57 | 5.87% | 8.05% | 21.39% | — | |
| $653.11 | $18.23B | 35.78 | 19.97% | 18.24% | 99.76% | — | |
| $204.74 | $15.68B | 35.32 | -0.37% | 5.45% | 4.85% | — | |
| $11.96 | $1.95B | 48.42 | -7.16% | 0.91% | 2.04% | 2.74% | |
| $366.57 | $30.06B | 29.79 | 7.25% | 6.88% | 11.52% | 0.78% |
Charles River Laboratories International, Inc. (CRL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Charles River Laboratories International, Inc. (CRL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 5, 2026·SEC
May 11, 2026·SEC
Get notified when CRL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Charles River Laboratories International, Inc. (CRL) stock FAQ — growth, dividends, profitability & financials explained
Charles River Laboratories International, Inc. (CRL) reported $3.98B in revenue over the trailing twelve months. Revenue was $4.02B in fiscal year 2025. That is 1977% more than the $193.3M of fiscal year 1998.
Charles River Laboratories International, Inc. (CRL) revenue fell by 1.2% over the trailing twelve months, compared with the twelve months before.
Yes. Charles River Laboratories International, Inc. (CRL) earned $40.2M in net income over the trailing twelve months (a 1.0% net margin).
Charles River Laboratories International, Inc. (CRL) had a return on equity (ROE) of 1.3% over the trailing twelve months. That is below the market's typical 10-15%.
Charles River Laboratories International, Inc. (CRL) generated $399.6M in free cash flow over the trailing twelve months.
